At Investor Meeting, RXi Updates Pipeline, Discloses Details About Oral-Delivery Tech

In addition to ALS and hypercholesterolemia, RXi has now added Alzheimer’s disease and inflammatory disease to the list of disease areas on which it is focusing. The company, however, made no mention of its work in cancer.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories